Targeting oncogene dependence and resistance
- PMID: 12781357
- DOI: 10.1016/s1535-6108(03)00115-6
Targeting oncogene dependence and resistance
Abstract
Our expanding experience with imatinib mesylate provides instructive lessons on the power and pitfalls of targeted therapy. The often impressive initial clinical responses seen with imatinib in a variety of malignancies inevitably give way to the emergence of resistant disease. Recent findings reveal several mechanisms of resistance and suggest ways to overcome them.
Comment on
-
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.Cancer Cell. 2003 May;3(5):459-69. doi: 10.1016/s1535-6108(03)00108-9. Cancer Cell. 2003. PMID: 12781364
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources